An interventional study of Alkalizing Fruit and Vegetables and Sodium bicarbonate in Chronic Kidney Diseases and Metabolic Acidosis, sponsored by Dylan MacKay. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Dylan MacKay · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 146th largest by enrollment of the 173 interventional ones that give a count, is one of 10 that started in 2023, is one of 62 with no phase, and was the 141st registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Canada, United States, Argentina and 24 more countries
Ages 18–99
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 34 more countries
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 35 · Phase 3 61 · Phase 4 15
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 195 across the 173 interventional studies, 500 across the 41 observational. Of the 143 that completed or were terminated, 58 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 215 have an industry lead sponsor. The 10 most frequent:
Dylan MacKay is the lead sponsor of 3 studies on the registry; none are open to participants now.
Dylan MacKay has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
14 of the studies in Renal Insufficiency, Chronic with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 14 to your calendar (.ics) → With an account.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic acidosis is a common problem that occurs with worsening chronic kidney disease. Dietary acid can build up when the kidneys are not working well. This can be associated with a higher risk of worsening kidney function and death. The usual treatment is a medication called sodium bicarbonate which works to balance the acids in the body. The medication however often does not work and causes side effects. Consumption of alkalizing fruit and vegetables may work as a treatment for metabolic acidosis. This trial is being done to see if fruit and vegetables, provided via home delivery, can become a viable management for metabolic acidosis in patients with chronic kidney disease.
Metabolic acidosis is a common complication of advanced chronic kidney disease (CKD). As kidney function declines, the ability to excrete excess dietary acid is reduced. This can lead to the development of metabolic acidosis, an imbalance in the body's acid-base balance. Metabolic acidosis is associated with a higher risk of CKD progression and mortality. Typical treatment includes an oral alkali, such as sodium citrate or sodium bicarbonate. Recent studies have shown that the treatment of metabolic acidosis can reduce the decline in kidney function and potentially prevent progression of CKD to dialysis. Treatment rates with an oral alkali are low because the treatments are ineffective, often poorly tolerated, and may be associated with net harm. Base producing fruit and vegetables are a potential treatment of metabolic acidosis by reducing the dietary contribution to overall acid load that must be managed by the kidneys. A recent systematic review and meta-analysis of clinical trials using oral alkali supplements or reduction in dietary acid intake using fruits and vegetables, when compared to no treatment, usual care or placebo found that these treatments increased serum bicarbonate and slowed the decline of kidney function. Fruit and vegetables are an effective and well-tolerated therapy for the treatment of metabolic acidosis in CKD. While oral alkali therapy has known adverse effects, important limitations also exist in the widespread applicability of fruit and vegetables as a treatment for metabolic acidosis. Only 2 single center randomized trials have examined the efficacy of fruit and vegetables for the management for acidosis. This dual-center trial will be the first randomized trial in Canada to evaluate the feasibility of providing fruit and vegetables via home delivery to patients for the management of metabolic acidosis in CKD. This study will be critical in designing a pan-Canadian phase 3 trial testing the efficacy of alkalizing fruit and vegetable provision on slowing the progression of CKD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session from a registered dietitian (RD), following randomization, either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
Dietary Supplement: Alkalizing Fruit and Vegetables
Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level \>22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
Drug: Sodium bicarbonate
The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the dispensed by the clinic/hospital pharmacies.
Randomization to preliminary eligible ratio
Ratio of randomized to preliminary eligible greater, calculated among all patients approached to participate expressed as percentage will be collected at 12 months to investigate fruit and vegetable intervention feasibility. A red, yellow, green framework has been developed as a feasibility metric: green for ratios more than 50%, yellow for ratios 20%-49.9%, and red for ratios less than 20%
Time frame: 12 months
Weekly recruitment rate
Number of new participants per weeks of active recruitment. A green, yellow, red feasibility framework has been developed as a feasibility metric: green for ≥ 0.5 , yellow for 0.125-0.49 and red for \< 0.125
Time frame: 12 months
Study outcome follow up
Study outcome follow up expressed as a percentage, will be calculated at 12 months to investigate the fruit and vegetable intervention feasibility. A red, yellow, green feasibility framework has been developed as a feasibility metric: green for ≥ 95% , yellow for 80%-94.9% and red for \<80%.
Time frame: 12 months
Potential renal acid load (PRAL) in mEq/day
Calculated from average dietary intake assessed by Automated Self-Administered 24-hour Canada (ASA24) dietary recall survey conducted over three days. a red, yellow, green feasibility framework has been developed as a feasibility metric: green for \> 75% , yellow for 50%-75% and red for \<50%.
Time frame: Baseline, 6, and 12 months
Five repetition chair stand time
the amount of time it takes for a participant to get up out of a chair five times measured in seconds
Time frame: Baseline, 3, 6, 9, and 12 months
Physical function related quality of life
Participants will complete the SF-12 physical component score of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire. The questionnaire is scored between 0-100 with higher values representing physical function related quality of life.
Time frame: Baseline, 3, 6, 9, and 12 months
Serum bicarbonate (total CO2)
Serum bicarbonate concentration in milliequivalents per liter (mEq/L)
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Albumin
blood albumin is measured in grams per deciliter (g/dL)
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Calcium
Total blood calcium concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Estimated Glomerular Filtration Rate (eGFR)
calculated from serum creatinine, sex, and age, reported in mL/min/1.73 m2
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Glucose
Total blood glucose concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Potassium
The total blood potassium concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Chloride
Total blood chloride concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Sodium
The total sodium concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Phosphorus
The total blood phosphorus concentration in mmol/L
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Hemoglobin A1c
Hemoglobin A1c in percentage
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Blood Urea Nitrogen (BUN)
Blood Urea Nitrogen (BUN) is reported in millimole per litre (mmol/L)
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Urine Albumin/Creatinine Ratio
The ratio of albumin to creatinine concentrations in urine, reported in Milligrams albumin per millimole creatinine
Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)
Changes in medication
Research coordinator will update information on concomitant medications or supplements information with the participant
Time frame: Baseline,1, 3, 6, 9, and 12 months
Systolic blood pressure in mmHg
Blood pressure will be measured in triplicate using a validated blood pressure monitor following Kidney Disease: Improving Global Outcomes (KDIGO) 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Time frame: Baseline, 1, 3, 6, 9, and 12 months
Diastolic blood pressure in mmHg
Blood pressure will be measured in triplicate using a validated blood pressure monitor following KDIGO 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Time frame: Baseline, 1, 3, 6, 9, and 12 months
Edmonton Symptom Assessment System (ESAS) - Revised Renal
A questionnaire used to rate the intensity of nine common symptoms experienced by renal patients, including pain, tiredness, drowsiness, nausea, appetite levels, shortness of breath, depression and anxiety levels, and well-being. Minimum value 0 and maximum value 100 with higher values being worse.
Time frame: Baseline, 3, 6, 9, and 12 months
All cause hospitalization
Information on recent hospitalizations from participant's clinical records will be collected.
Time frame: 3, 6, 9, and 12 months
All cause mortality
Information on mortality from participant's clinical records will be collected.
Time frame: 3, 6, 9, 12 months
Height
Height will be measured using a validated stadiometer in centimeters..
Time frame: Baseline, 3, 6, 9, and 12 months
Weight
Weight will be measured using a calibrated scale in kilograms.
Time frame: Baseline, 3, 6, 9, and 12 months
Body Mass Index (BMI)
MBI will be calculated through dividing weight in kilograms (kg) by the square of height in meters (m2).
Time frame: Baseline, 3, 6, 9, and 12 months
Exit Interviews
Upon the completion of the 12 months of study, the participants will be invited to participate in an exit interview. This interview will involve a few open ended question and its goal is to better understand participants' personal experiences and perspectives of the study and the intervention they received, as well as their overall viewpoints of trials such as ReDACKD, as a person living with CKD and metabolic acidosis. We will offer the interview to all of the participants at the final visit of the trial; however, taking part is this interview is voluntary. The "Exit Interview Consent Form" will be used to explain the aims and procedures of the interview
Time frame: Final Visit (Month 12)-After the completion of the trial
Ran from Aug 2023 to primary completion in Sep 2026, 37 months.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 37 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →